Prodrugs of Phosphonates, Phosphinates, and Phosphates

作者: Gong-Xin He , Jeffrey P. Krise , Reza Oliyai

DOI: 10.1007/978-0-387-49785-3_25

关键词:

摘要: The aim of this chapter is to review the recent progress in design and development prodrugs phosphonate, phosphinate, phosphate functional groups improve their physicochemical properties, membrane permeability, oral bioavailability, drug targeting. Phosphonates, phosphinates, phosphates are prominently represented as pharmacophores various classes biological agents. These include antiviral anticancer nucleotides, inhibitors biosynthesis cholesterol, angiotensin-converting enzyme inhibitors, bisphosphonates for treatment osteoporosis. It generally well recognized that therapeutic potential drugs containing a or group limited by inadequate permeation absorption. Phosphonate, carry one two negative charges at physiological pH values making them very polar (Figure 1). This high polarity basis many deficiencies terms delivery. Specifically, ionized species do not readily undergo passive diffusion across cellular membranes. Because polarity, these agents often exhibit low volume distribution and, therefore, tend be subject efficient renal clearance possibly biliary excretion.

参考文章(71)
Mn Arimilli, Cu Kim, J Dougherty, A Mulato, R Oliyai, Jp Shaw, Kc Cundy, N Bischofberger, Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs Antiviral Chemistry & Chemotherapy. ,vol. 8, pp. 557- 564 ,(1997) , 10.1177/095632029700800610
Reza Oliyai, Jeng‐Pyng Shaw, Cathy M. Sueoka‐Lennen, Kenneth C. Cundy, Murty N. Arimilli, Robert J. Jones, William A. Lee, Aryl ester prodrugs of cyclic HPMPC. I : Physicochemical characterization and in vitro biological stability Pharmaceutical Research. ,vol. 16, pp. 1687- 1693 ,(1999) , 10.1023/A:1018945713623
Kenneth C. Cundy, James A. Fishback, Jeng‐Pyng Shaw, Min L. Lee, Kenneth F. Soike, Gary C. Visor, William A. Lee, Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharmaceutical Research. ,vol. 11, pp. 839- 843 ,(1994) , 10.1023/A:1018925723889
Micheline Piquette‐Miller, Fakhreddin Jamali, Selective Effect of Adjuvant Arthritis on the Disposition of Propranolol Enantiomers in Rats Detected Using a Stereospecific HPLC Assay Pharmaceutical Research. ,vol. 10, pp. 294- 299 ,(1993) , 10.1023/A:1018907431893
Sunanda A. Ranadive, Andrew X. Chen, Abu T. M. Serajuddin, Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharmaceutical Research. ,vol. 9, pp. 1480- 1486 ,(1992) , 10.1023/A:1015823315983
Sally Freeman, Kenneth C. Ross, 3 Prodrug Design for Phosphates and Phosphonates Progress in Medicinal Chemistry. ,vol. 34, pp. 111- 147 ,(1997) , 10.1016/S0079-6468(08)70106-1
László Révész, Per-Henrik Magnusson, George Klein, Peter Reichard, Ola Sköld, Studies on Resistance against 5-Fluorouracil I. Enzymes of the Uracil Pathway during Development of Resistance Cancer Research. ,vol. 22, pp. 235- 243 ,(1962)
Jeng‐Pyng Shaw, Cathy M. Sueoka, Reza Oliyai, William A. Lee, Murty N. Arimilli, Choung U. Kim, Kenneth C. Cundy, Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharmaceutical Research. ,vol. 14, pp. 1824- 1829 ,(1997) , 10.1023/A:1012108719462
László Révész, Per-Henrik Magnusson, Ola Sköld, Studies on resistance against 5-fluorouracil. III. Selective value of resistant, uridine kinase-deficient tumor cells. Cancer Research. ,vol. 22, pp. 1226- 1229 ,(1962)